MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
The Transapical Route for TAVR
Recent data regarding transapical access for transcatheter aortic valve replacement, as well as the devices used in this procedure.
By Rafal Dworakowski, MD, PhD, and Olaf Wendler, MD, PhD, FRCS
Primary Endpoint Data From Postmarket JUPITER Registry Presented for JenaValve TAVI System
May 22, 2014—JenaValve Technology, Inc. announced that results from the JUPITER (JenaValve Evaluation of Long-Term Performance and Safety in Patients With Severe Aortic Stenosis Registry) trial were presented at the EuroPCR 2014 congress in Paris, France.
Postapproval SOURCE 3 Registry Evaluates Edwards Sapien 3 TAVR Device in Real-World Use
May 17, 2016—Edwards Lifesciences announced that 30-day data from its European postapproval study of its Sapien 3 transcatheter aortic heart valve replacement (TAVR) device demonstrated positive patient outcomes, including the lowest reported mortality and stroke rates seen in the SOURCE family of registries.
Real-World Use of Edwards' Sapien 3 TAVR System Evaluated in SOURCE 3 Registry Data
May 16, 2017—Edwards Lifesciences announced that new 1-year data from the SOURCE 3 Registry, a large European postapproval study of the company's Sapien 3 transcatheter heart valve, demonstrated positive patient outcomes, including high survival rates and low rates of stroke and paravalvular leak.
Edwards Sapien XT Approved in Europe for Mitral and Aortic Valve-in-Valve Procedures
February 5, 2014—Edwards Lifesciences (Irvine, CA) announced it has received European CE Mark approval for valve-in-valve procedures using the company’s Sapien XT transcatheter heart valve for patients whose surgical mitral or aortic valves require replacement and who are at extreme risk for surgery.
Chief Medical Editor's Page: Transcatheter Valve Update
By Ted E. Feldman, MD, FSCAI
Postmarket SOURCE Registry Data Show Successful 1-Year Outcomes for Edwards Sapien Valve
May 20, 2011—Edwards Lifesciences Corporation (Irvine, CA) announced that data from the postmarket European SOURCE registry studying the first 2 years of commercialization of the Edwards Sapien valve were presented at the EuroPCR 2011 conference in Paris.
First-in-Human Experience Presented for Cardiosolutions' Mitra-Spacer System
September 22, 2015—Cardiosolutions, Inc. announced the presentation of the first-in-human experience with the Mitra-Spacer system, an atraumatic, volume-adjustable, mitral valve therapeutic device.
One-Year Postmarket Data Presented for Edwards Sapien Transcatheter Heart Valve
May 25, 2010—Edwards Lifesciences (Irvine, CA) announced that Martyn Thomas, MD, presented 1-year data from the company's SOURCE registry at the EuroPCR 2010 conference in Paris.
